Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bluestep Bank AB (publ) Year-end report 2022

The year in briefPerformance and financial position · Lending to the public increased by 11% to MSEK 20,346 (MSEK 18,333). Adjusted for currency effects the increase was 9%. · New lending amounted to MSEK 6,903 (MSEK 7,169). Adjusted for currency effects the decrease was 6%, as both NOK and EUR strengthened against SEK compared to the previous year. · Net interest income amounted to MSEK 921 (MSEK 833), an increase of 11%. · Operating profit amounted to MSEK 310 (MSEK 325). Operating income increased during the year, but non-recurring items associated with the strategic review

Cantargia publishes full year report for 2022

Cantargia AB’s (”Cantargia”) full year report for 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the fourth quarter · A milestone was reached in the CAPAFOUR and CESTAFOUR trials when enough patients had been enrolled to end recruitment. Cantargia announced that clinical development of nadunolimab will focus on randomized studies. The CIRIFOUR trial was also stopped. · New results showing the effect of nadunolimab on various tumor-promoting molecules were presented at the SITC conference. · New positive

Year-end report 2022

GARO LAUNCHES NEW PRODUCT PROGRAM IN DESTINATION CHARGING IN AN OTHERWISECHALLENGING QUARTER OCTOBER-DECEMBER 2022 · Net sales amounted to MSEK 341.8 (370.1). · Net sales declined 8% (+21). · EBIT amounted to MSEK 8.9 (57.7). · EBIT margin amounted to 2.6% (15.6). · Net income was MSEK 7.0 (46.4). · Earnings per share amounted to SEK 0.14 (0.93). · Non-recurring costs of MSEK 15.0 were charged to EBIT. JANUARY-DECEMBER 2022 · Net sales amounted to MSEK 1,390.5 (1,295.8). · Net sales increased 7% (25). · EBIT amounted to MSEK 152.8 (207.2). · EBIT

Quickbit introduces a cost-saving program with the ambition to significantly reduce operational costs

Today, Quickbit announces that a review of the organisation has been carried out with the aim of reducing costs. As part of the review, Quickbit is initiating a cost-saving program that involves streamlining operations and staff reductions.Quickbit has continuously been working on cost savings for a period, but is now carrying out a cost saving program during 2023 to further reduce costs. The ambition is to simplify and streamline organisational processes. As a result, Quickbit will discontinue live-presentations in connection with quarterly reports. The workforce will also be reduced by

Immunovia Publishes Full Year Report for 2022

October-December 2022 · Net sales amount kSEK 502 (305) divided by sales of tests kSEK 190 (278) and royalties kSEK 312 (27). · Net earnings amount MSEK -67 (-47) and earnings per share before and after dilution were SEK -2.97 (-2.08). · Cash Flow from operating activities amount MSEK -51 (-50). · Cash and equivalents at the end of the period amounted to MSEK 106 (287). · On October 12, the Company announced a positive update on its physician experience program with IMMray™ PanCan-d. Thus far the program has included 23 high risk surveillance centers around the U.S. thus

Year-end report Quartiers Properties January – December 2022

Quartiers Properties AB (publ) today publishes the company's year-end report for the period January to December 2022.JANUARY–DECEMBER 2022 · Net sales in 2022 totalled SEK 203,387 (156,476) thousand, corresponding to 30% growth. · Revenue from operator activities was SEK 89,116 (64,513) thousand, corresponding to 38% growth. Proceeds from the divestment of properties during the period totalled SEK 114,271 (91,963) thousand and relate to the sale of 29 apartments in hacienda collection. · The company's cash flow from the sale of project and operating properties totalled SEK 109,

Interim Report Fourth Quarter and Annual Financial Statement Release 2022

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2022 – 31.12.2022. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “Q4 2022 marked long awaited milestones that will help us grow sales and expand our market-leadership. We added new licensed products in Denmark and Norway and realized net sales of 2.8 mDKK during the

Polymer Factory publishes memorandum relating to the rights issue

NOT FOR PUBLICATION, DISCLOSURE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, CANADA, JAPAN, SOUTH KOREA, AUSTRALIA, NEW ZEALAND, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND, UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD BE ILLEGAL OR REQUIRE ADDITIONAL REGISTRATION ACTIONS OR OTHER ACTIONS BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. The Board of Directors of Polymer Factory Sweden AB (“Polymer Factory” or the “Company”) today, 23 February 2023, publishes

New study examines soaring drug prices

Drug prices have long been a widely debated topic. In a new British study, researchers argue that pharmaceutical companies cannot use high development costs as motivation  for the soaring prices — especially as most new drugs provide  rather limited improvements in clinical benefit compared to  existing treatments.Read the full article at biostock.se : https://www.biostock.se/en/2023/02/new-study-examines-soaring-drug-prices/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release February 23, 2023 at 9:10 a.m. Nokian Tyres has received an announcement from BlackRock, Inc. on February 22, 2023, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the total holding in Nokian Tyres shares and voting rights owned by BlackRock, Inc. and its funds exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on February 21, 2023. The total shareholding of BlackRock, Inc. in Nokian Tyres has increased to 7,101,825 shares,

Successful H2 boosts LeadDesk’s revenue growth to 14% with a 14 % EBITDA margin

Unofficial translation of press release 23 February 2023, 9.00 am. In case the document differs from the original, the Finnish version prevails.LeadDesk Plc Financial Statements Summary 1/1–31/12/2022 Figures in parentheses refer to the equivalent period in the previous year unless otherwise stated. Figures presented in this press release are unaudited. July–December 2022 · Revenue EUR 14,320 (12,545) thousand, growth 14.1% · Comparable pro forma revenue* EUR 14,320 (12,691) thousand, growth 12.8% · Annual recurring revenue contract base EUR 24,300 (23,228**) thousand,

Volvo leads the booming market for electric trucks

Last year, the number of heavy electric trucks on the roads in Europe and the United States grew faster than ever before. Volvo Trucks have now sold more than 4,300 electric trucks globally in more than 38 countries. In Europe, Volvo Trucks is the market leader with a 32% share of the market for heavy electric trucks, and in North America, nearly half of all heavy electric trucks registered in 2022 were Volvo trucks. Volvo Trucks has sold more than 4,300 electric trucks in more than 38 countries around the world. In 2022 the market for heavy (≥16 tonnes) electric trucks in

AstraZeneca enters agreement with KYM for CMG901

23 February 2023 07:00 GMT AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate CMG901 expands AstraZeneca's commitment in gastric cancer AstraZeneca and KYM Biosciences Inc.[i] have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally. CMG901

Bricknode year-end report 2022

Bricknode has today published its year-end report 2022. The report is attached to this press release and is available on the Bricknode website .October – December 2022 · Net revenue increased by 9% to 4,647 (4,271) TSEK · Net revenue retention rate 98% (115%) · Earnings per share amounted to -0,56 (-0,88) SEK · EBIT result amounted to -5,214 (-3,725) TSEK and the margin amounted to -112% (-87%) · Agreements signed with three new wealth management customers January – December 2022 · Net revenue

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during 12th exercise period

Catena Media plc today announces that the 12th period to subscribe for shares in the company by exercise of warrants (ticker CTM TO1) (“the warrants”) commences today, 23 February 2023, and will run until and including 4 March 2023. During this period, each warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 18.90. Payment of subscribed shares can be made in cash or through set-off with the full nominal amount of each hybrid capital security (ticker CATME HO1) that the warrant holder uses for set-off. The nominal amount of one (1)

Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported favorable safety and promising early signs of efficacy following an initial analysis of the phase Ib part of the clinical trial TRIFOUR. In collaboration with the Spanish Breast Cancer Group (GEICAM), this trial investigates the IL1RAP-binding antibody nadunolimab (CAN04) in combination with chemotherapy for treatment of triple-negative breast cancer (TNBC). In 12 patients treated long enough for evaluation, the response rate was well above previously reported data for chemotherapy alone. The trial is now expanding into the

Annual Report for the fiscal year 2022

Copenhagen, Denmark, 23 February 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year of 2022. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: "2022 was a pivotal year characterized by intensive strategic work. Much progress has been made since our IPO just two years ago, not least with the presentation of positive results from multiple investigator-initiated studies with uTRACE[®]. During

Kährs Group: Year-End Report 2022

Continued strong profitability despite a slow-down in demandThe fourth quarter, October-December · Net sales amounted to SEK 937 million (867), which was a growth of 8 per cent. Organic growth was 0 per cent. Residential Nordics, Residential North America and our Commercial segment within Health care & Education continued to be strong, while sales in Residential West & South Europe slowed sharply · Operating EBITA amounted to SEK 108 million (73), corresponding to an operating margin of 11.5 per cent (8.4). · Operating profit totalled SEK 75 million (61), corresponding to an

InDex Pharmaceuticals Holding AB (publ) year-end report 2022

PK Study fully recruited”Given the dose selection in Q4 2023 our near-term focus remains on increasing the speed of site and patient recruitment and we look forward to seeing the results of our action plan bear fruit in 2023”, said Jenny Sundqvist, CEO of InDex Pharmaceuticals. Period October – December 2022 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –58.2 (–22.7) million · Result after tax amounted to SEK –56.3 (–22.8) million, corresponding to SEK –0.11 per share (–0.04) before and after dilution · Cash flow from operating activities

Volvo leads the booming market for electric trucks

Last year, the number of heavy electric trucks on the roads in Europe and the United States grew faster than ever before. Volvo Trucks have now sold more than 4,300 electric trucks globally in more than 38 countries. In Europe, Volvo Trucks is the market leader with a 32% share of the market for heavy electric trucks, and in North America, nearly half of all heavy electric trucks registered in 2022 were Volvo trucks.In 2022 the market for heavy (≥16 tonnes) electric trucks  in Europe, grew by 200% to 1,041 trucks,

Nordic Mining and Orion Resource Partners signs USD 55 million binding investment agreement

Nordic Mining ASA (“Nordic Mining” or the “Company”) is pleased to announce that its wholly owned subsidiary Nordic Rutile AS has signed binding agreements with a fund managed by Orion Resource Partners (“Orion”) for USD 55 million investment in the Engebø Rutile and Garnet Project (the “Engebø Project”). The investment comprises a USD 50 million non-dilutive royalty instrument to Nordic Rutile AS and USD 5 million in equity, which will be contributed to Nordic Mining ASA. The royalty instrument is secured, subordinate to the USD 100 million senior secured bond issued on 9 November 2022,

Photocure ASA: Results for the fourth quarter of 2022

Oslo, Norway, 23 February 2023 Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.9 million in the fourth quarter of 2022 (Q4 2021: NOK 94.2 million), and an EBITDA of minus NOK 16.9 million (NOK -5.5 million). The total revenues increased 10% to NOK 104.2 million and there were 57 blue light towers placed in the quarter, a record high for expanding the installed base of blue light cystoscopes. Photocure expects to deliver new Saphira™ blue light tower installations in the range of 65 to 75, consolidated product revenue growth above 20%, and positive EBITDA (ex-

There are no items matching the current filter
There are no more items matching the current filter
Back to top